8 ud af 8 tidsskrifter valgt, søgeord (covid) valgt, emner højest 180 dage gamle, sorteret efter nyeste først.
148 emner vises.
101
Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2023
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
This report describes influenza, updated COVID-19, and respiratory syncytial virus vaccination coverage among adults.
Læs mere
102
Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19 Vaccines Among Nursing Home Residents - National Healthcare Safety Network, United States, December 2023
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
This report describes respiratory syncytial virus, influenza, and COVID-19 vaccination coverage among nursing home residents.
Læs mere
103
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
This report describes data from two randomized, double-blind clinical trials that investigated COVID-19 rebound following treatment with or without nirmatrelvir/ritonavir.
Læs mere
104
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
CDC reviewed COVID-19 rebound studies among patients who did and did not receive antiviral treatment.
Læs mere
105
New Research Aims to Unravel Both ME/CFS and Long COVID
Medscape Infectious Diseases, 21.12.2023
Tilføjet 21.12.2023
A 2-day research conference sponsored by the US National Institutes of Health highlighted research that points to mechanisms that suggest potentially \'druggable\' pathways. Medscape Medical News
Læs mere
106
COVID Strain JN.1 Is Now a 'Variant of Interest,' WHO Says
Medscape Infectious Diseases, 21.12.2023
Tilføjet 21.12.2023
JN.1 was previously grouped with its relative, BA.2.86, but has increased so much in the past 4 weeks that the WHO moved it to standalone status. WebMD Health News
Læs mere
107
COVID Strain JN.1 Is Now a 'Variant of Interest,' WHO Says
Medscape Infectious Diseases, 21.12.2023
Tilføjet 21.12.2023
JN.1 was previously grouped with its relative, BA.2.86, but has increased so much in the past 4 weeks that the WHO moved it to standalone status. Medscape Medical News
Læs mere
108
Long-COVID Risks Vary Widely by State, Region: New Study
Medscape Infectious Diseases, 19.12.2023
Tilføjet 19.12.2023
The analysis in PLOS ONE also found that people struggling with long COVID are more likely to report mental health or mobility problems, according to the analysis. Medscape Medical News
Læs mere
109
Impact of the COVID-19 pandemic on prevalence of highly resistant microorganisms in hospitalised patients in the Netherlands, March 2020 to August 2022
Wieke Altorf-van der Kuil, Cornelia CH Wielders, Romy D Zwittink, Sabine C de Greeff, Dave A. Dongelmans, Ed J Kuijper, Daan W Notermans, Annelot F Schoffelen and on behalf of the study collaborators ISIS-AR study group
Eurosurveillance latest updates, 15.12.2023
Tilføjet 15.12.2023
BackgroundThe COVID-19 pandemic resulted in adaptation in infection control measures, increased patient transfer, high occupancy of intensive cares, downscaling of non-urgent medical procedures and decreased travelling. AimTo gain insight in the influence of these changes on antimicrobial resistance (AMR) prevalence in the Netherlands, a country with a low AMR prevalence, we estimated changes in demographics and prevalence of six highly resistant microorganisms (HRMO) in hospitalised patients in the Netherlands during COVID-19 waves (March–June 2020, October 2020–June 2021, October 2021–May 2022 and June–August 2022) and interwaves (July–September 2020 and July–September 2021) compared with pre-COVID-19 (March 2019–February 2020). MethodsWe investigated data on routine bacteriology cultures of hospitalised patients, obtained from 37 clinical microbiological laboratories participating in the national AMR surveillance. Demographic characteristics and HRMO prevalence were calculated as proportions and rates per 10,000 hospital admissions. ResultsAlthough no significant persistent changes in HRMO prevalence were detected, some relevant non-significant patterns were recognised in intensive care units. Compared with pre-COVID-19 we found a tendency towards higher prevalence of meticillin-resistant Staphylococcus aureus during waves and lower prevalence of multidrug-resistant Pseudomonas aeruginosa during interwaves. Additionally, during the first three waves, we observed significantly higher proportions and rates of cultures with Enterococcus faecium (pooled 10% vs 6% and 240 vs 120 per 10,000 admissions) and coagulase-negative Staphylococci (pooled 21% vs 14% and 500 vs 252 per 10,000 admissions) compared with pre-COVID-19. ConclusionWe observed no substantial changes in HRMO prevalence in hospitalised patients during the COVID-19 pandemic.
Læs mere
110
Notes from the Field: COVID-19 Pandemic-Related Changes in Blood Lead Screening - Chicago, Illinois, 2017-2022
Morbidity and Mortality Weekly Report (MMWR), 14.12.2023
Tilføjet 14.12.2023
This report describes decreases in blood lead level testing among young children during the COVID-19 pandemic.
Læs mere
111
Reporting Protocol for integrated respiratory virus surveillance, version 1.4
ECDC
ECDC COVID-19 updates, 13.12.2023
Tilføjet 13.12.2023
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mere
112
Federal Program Offers Free COVID, Flu At-Home Tests, Rx
Medscape Infectious Diseases, 9.12.2023
Tilføjet 9.12.2023
The Home Test to Treat program is virtual and offers at-home rapid tests, telehealth sessions, and at-home treatments to people nationwide. WebMD Health News
Læs mere
113
Wide Regional Variation in Diagnosis of Long COVID
Medscape Infectious Diseases, 8.12.2023
Tilføjet 8.12.2023
The percentage of patients with a U09.9 diagnostic code in the year after a SARS-CoV-2 infection ranged from less than 4% in one region to more than 24% in another Medscape Medical News
Læs mere
114
Anxiety, Depression Soared in Young Adults During Pandemic
Medscape Infectious Diseases, 8.12.2023
Tilføjet 8.12.2023
More than a third of young adults living in the US during the COVID-19 pandemic experienced anxiety and/or depression, an outcome that may be related to economic or social uncertainty. Medscape Medical News
Læs mere
115
Factors associated with parental intention to vaccinate their child against influenza, Finland, February to March, 2022: a web-based survey
Idil Hussein, Simopekka Vänskä, Jonas Sivelä, Tuija Leino and Hanna Nohynek
Eurosurveillance latest updates, 8.12.2023
Tilføjet 8.12.2023
BackgroundInfluenza vaccination for children aged 6 months to 6 years is included in the national vaccination programme in Finland. Although all vaccines in the programme are free of charge, national coverage of influenza vaccination among children under 3 years and 3–6 years during 2020/21 was 43% and 35% respectively, with regional differences. AimTo assess factors underlying parental vaccination intention in order to increase influenza vaccine uptake among children. MethodsWe conducted a web-based survey among parents (n = 17,844) of randomly selected eligible children (aged 6 months–6 years) in February–March 2022 in five Finnish municipalities from regions of high and low coverage. Logistic regressions were used to determine associations between vaccination intention and e.g. sociodemographic factors, attitudes and knowledge. Linkage to the national vaccination register was used to confirm realisation of vaccination intention after the study. ResultsParticipation rate was 13% (n = 2,322 parents). Influenza knowledge, trust in official information, responding parent’s education level, adherence to the vaccination programme, number of children and changes in attitudes towards vaccination since COVID-19 were all associated with intention to vaccinate. Vaccination intention for children was 64%, and realised vaccination 51%. ConclusionDespite the low participation rate, both vaccinated and unvaccinated children were represented. Influenza vaccine uptake is not dependent on a single factor. Our results identified the need for open dialogue between parents and healthcare professionals, as the lack of vaccine being offered by healthcare professionals was the most reported reason for not vaccinating.
Læs mere
116
New COVID Variant JN.1 Could Disrupt Holiday Plans
Medscape Infectious Diseases, 7.12.2023
Tilføjet 7.12.2023
\'A significant wave [of JN.1] has started here and could be blunted with a high booster rate and mitigation measures.\' WebMD Health News
Læs mere
117
Some Reasons to Get Off the Fence About COVID Booster
Medscape Infectious Diseases, 7.12.2023
Tilføjet 7.12.2023
Though many people remain on the fence about getting the latest COVID vaccine booster, new research suggests a strong argument for getting the shot this winter. Medscape Medical News
Læs mere
118
Geriatricians, Look Out for Patients With Long COVID
Medscape Infectious Diseases, 6.12.2023
Tilføjet 6.12.2023
Patients residing in nursing homes may exhibit signs of long COVID that are missed. Medscape Medical News
Læs mere
119
COVID, Flu Rates Rising Nationwide, but RSV May Have Peaked
Medscape Infectious Diseases, 6.12.2023
Tilføjet 6.12.2023
COVID-19 appears to be heading for a holiday season increase across most of the United States. WebMD Health News
Læs mere
120
COVID Vaccines Lower Risk of Serious Illness in Kids
Medscape Infectious Diseases, 1.12.2023
Tilføjet 1.12.2023
Two doses of an mRNA COVID-19 vaccine reduced hospitalizations and emergency department visits by 40%. Medscape Medical News
Læs mere
121
COVID Vaccines Likely Reversed Premature Birth Trend
Medscape Infectious Diseases, 1.12.2023
Tilføjet 1.12.2023
Researchers suggest this provides further evidence of benefit of SARS-CoV-2 vaccination before or during pregnancy. Medscape Medical News
Læs mere
122
Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case–control study, United Kingdom, 2022
Anastasia Chatzilena, Catherine Hyams, Rob Challen, Robin Marlow, Jade King, David Adegbite, Jane Kinney, Madeleine Clout, Nick Maskell, Jennifer Oliver, Adam Finn, Leon Danon and on behalf of The Avon CAP Research Group
Eurosurveillance latest updates, 1.12.2023
Tilføjet 1.12.2023
BackgroundUnderstanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is a public health priority. A precise analysis of the rVE of monovalent and bivalent boosters given during the 2022 spring-summer and autumn-winter campaigns, respectively, in a defined population remains of interest. AimWe assessed rVE against hospitalisation for the spring-summer (fourth vs third monovalent mRNA vaccine doses) and autumn-winter (fifth BA.1/ancestral bivalent vs fourth monovalent mRNA vaccine dose) boosters. MethodsWe performed a prospective single-centre test-negative design case–control study in ≥ 75-year-old people hospitalised with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling for age, sex, socioeconomic status, patient comorbidities, community SARS-CoV-2 prevalence, vaccine brand and time between baseline dose and hospitalisation. ResultsWe included 682 controls and 182 cases in the spring-summer booster analysis and 572 controls and 152 cases in the autumn-winter booster analysis. A monovalent mRNA COVID-19 vaccine as fourth dose showed 46.6% rVE (95% confidence interval (CI): 13.9–67.1) vs those not fully boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had 46.7% rVE (95% CI: 18.0–65.1), compared with a fourth monovalent mRNA COVID-19 vaccine dose. ConclusionsBoth fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offered similar protection against hospitalisation with Omicron infection to monovalent mRNA boosters given earlier in the year. These findings support immunisation programmes in several European countries that advised the use of BA.1/ancestral bivalent booster doses.
Læs mere
123
SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023
Morbidity and Mortality Weekly Report (MMWR), 1.12.2023
Tilføjet 1.12.2023
This report describes the effectiveness of COVID-19 mRNA vaccines among infants and children aged 6 months-4 years.
Læs mere
124
Interim analysis of COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in six European countries
ECDC
ECDC COVID-19 updates, 30.11.2023
Tilføjet 30.11.2023
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses, against hospitalisation due to COVID-19 and COVID-19 related deaths in resident populations ≥50 years of age, living in the community.
Læs mere
125
COVID Vax T-Cell Responses Help B-Cell–Deficient Patients
Medscape Infectious Diseases, 30.11.2023
Tilføjet 30.11.2023
The findings demonstrate how vaccine-induced T-cell responses could potentially reduce COVID-19 severity, the authors write. Medscape Medical News
Læs mere
126
New CDC Advisory Once Again Flags BA.2.86 COVID Variant
Medscape Infectious Diseases, 30.11.2023
Tilføjet 30.11.2023
An emerging variant of COVID-19 called BA.2.86 that caused alarm earlier this summer has landed on the CDC\'s radar again. WebMD Health News
Læs mere
127
New Tests May Finally Diagnose Long COVID
Medscape Infectious Diseases, 30.11.2023
Tilføjet 30.11.2023
Researchers have pinpointed a potential common link to the varying symptoms of long COVID and specific testing could solve the mystery. Medscape Medical News
Læs mere
128
Reporting Protocol for integrated respiratory virus surveillance, version 1.3
ECDC
ECDC COVID-19 updates, 28.11.2023
Tilføjet 28.11.2023
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mere
129
Pandemic Tied to a 50% Drop in Memory, Executive Function
Medscape Infectious Diseases, 27.11.2023
Tilføjet 27.11.2023
The first year of the COVID-19 pandemic is associated with a 50% decline in working memory and executive function among older adults, a new UK study suggests. Medscape Medical News
Læs mere
130
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
Angela MC Rose, Nathalie Nicolay, Virginia Sandonis Martín, Clara Mazagatos, Goranka Petrović, F Annabel Niessen, Ausenda Machado, Odile Launay, Sarah Denayer, Lucie Seyler, Joaquin Baruch, Cristina Burgui, Isabela I Loghin, Lisa Domegan, Roberta Vaikutytė, Petr Husa, George Panagiotakopoulos, Nassera Aouali, Ralf Dürrwald, Jennifer Howard, Francisco Pozo, Bartolomé Sastre-Palou, Diana Nonković, Mirjam J Knol, Irina Kislaya, Liem binh Luong Nguyen, Nathalie Bossuyt, Thomas Demuyser, Aušra Džiugytė, Iván Martínez-Baz, Corneliu Popescu, Róisín Duffy, Monika Kuliešė, Lenka Součková, Stella Michelaki, Marc Simon, Janine Reiche, María Teresa Otero-Barrós, Zvjezdana Lovrić Makarić, Patricia CJL Bruijning-Verhagen, Verónica Gomez, Zineb Lesieur, Cyril Barbezange, Els Van Nedervelde, Maria-Louise Borg, Jesús Castilla, Mihaela Lazar, Joan O’Donnell, Indrė Jonikaitė, Regina Demlová, Marina Amerali, Gil Wirtz, Kristin Tolksdorf, Marta Valenciano, Sabrina Bacci, Esther Kissling, I-MOVE-COVID-19 hospital study team and VEBIS hospital study team
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)-dominant periods, 2021. MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset. ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69–92) overall and 75% (95% CI: 42–90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18–74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57–98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose
Læs mere
131
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022
Angela MC Rose, Nathalie Nicolay, Virginia Sandonis Martín, Clara Mazagatos, Goranka Petrović, Joaquin Baruch, Sarah Denayer, Lucie Seyler, Lisa Domegan, Odile Launay, Ausenda Machado, Cristina Burgui, Roberta Vaikutyte, F Annabel Niessen, Isabela I Loghin, Petr Husa, Nassera Aouali, George Panagiotakopoulos, Kristin Tolksdorf, Judit Krisztina Horváth, Jennifer Howard, Francisco Pozo, Virtudes Gallardo, Diana Nonković, Aušra Džiugytė, Nathalie Bossuyt, Thomas Demuyser, Róisín Duffy, Liem binh Luong Nguyen, Irina Kislaya, Iván Martínez-Baz, Giedre Gefenaite, Mirjam J Knol, Corneliu Popescu, Lenka Součková, Marc Simon, Stella Michelaki, Janine Reiche, Annamária Ferenczi, Concepción Delgado-Sanz, Zvjezdana Lovrić Makarić, John Paul Cauchi, Cyril Barbezange, Els Van Nedervelde, Joan O’Donnell, Christine Durier, Raquel Guiomar, Jesús Castilla, Indrė Jonikaite, Patricia CJL Bruijning-Verhagen, Mihaela Lazar, Regina Demlová, Gil Wirtz, Marina Amerali, Ralf Dürrwald, Mihály Pál Kunstár, Esther Kissling, Sabrina Bacci, Marta Valenciano, I-MOVE-COVID-19 hospital study team and VEBIS hospital study team
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received
Læs mere
132
Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023
Bette Liu, Sandrine Stepien, Ketaki Sharma and Kristine Macartney
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
We followed 4,081,257 Australian adults aged ≥ 65 years between November 2022 and May 2023 for COVID-19-specific mortality, when recombinant SARS-CoV-2 Omicron lineages (predominantly XB and XBB) as well as BA.2.75 were circulating. Compared with a COVID-19 booster targeting ancestral SARS-CoV-2 given > 180 days earlier, the relative vaccine effectiveness against COVID-19 death of a bivalent (ancestral/BA.1 or ancestral/BA.4-5) booster given 8 to 90 days earlier was 66.0% (95%CI: 57.6 to 72.2%) and that of a monovalent ancestral booster given 8 to 90 days earlier was 44.7% (95%CI: 23.9 to 59.7%).
Læs mere
133
Notes from the Field: Diagnosis of Congenital Syphilis and Syphilis Among Females of Reproductive Age Before and During the COVID-19 Pandemic - Chicago, 2015-2022
Morbidity and Mortality Weekly Report (MMWR), 23.11.2023
Tilføjet 23.11.2023
This report describes increases in cases of congenital syphilis during the COVID-19 pandemic.
Læs mere
134
Chest Pain With Long COVID Common but Undertreated
Medscape Infectious Diseases, 22.11.2023
Tilføjet 22.11.2023
A Mayo Clinic study found nearly 90% of patients with long COVID experience chest pain, but treatment for this condition is not yet standardized. Medscape Medical News
Læs mere
135
A Long COVID Clinic's Fight to Meet Crushing Patient Needs
Medscape Infectious Diseases, 18.11.2023
Tilføjet 18.11.2023
\'This entire year has been really filled with patients that have been trying to get access to the clinic for a year. And they’re still struggling.\' Medscape Medical News
Læs mere
136
Early detection of the emerging SARS-CoV-2 BA.2.86 lineage through integrated genomic surveillance of wastewater and COVID-19 cases in Sweden, weeks 31 to 38 2023
Carmen Espinosa-Gongora, Carlo Berg, Moa Rehn, Javier Edo Varg, Lena Dillner, Neus Latorre-Margalef, Anna J Székely, Emmi Andersson and Elin Movert
Eurosurveillance latest updates, 17.11.2023
Tilføjet 17.11.2023
The SARS-CoV-2 BA.2.86 Omicron subvariant was first detected in wastewater in Sweden in week 31 2023, using 21 highly specific markers from the 50 investigated. We report BA.2.86’s introduction and subsequent spread to all 14 regions performing wastewater sampling, and on 70 confirmed COVID-19 cases, along with the emergence of sublineages JN.1 and JN.2. Further, we investigated two novel mutations defining the unique BA.2.86 branching in Sweden. Our integrated approach enabled variant tracking, offering evidence for well-informed public health interventions.
Læs mere
137
Rebound in community antibiotic consumption after the observed decrease during the COVID-19 pandemic, EU/EEA, 2022
Cèlia Ventura-Gabarró, Vivian H Leung, Vera Vlahović-Palčevski, Anna Machowska, Dominique L Monnet, Liselotte Diaz Högberg and ESAC-Net study group
Eurosurveillance latest updates, 17.11.2023
Tilføjet 17.11.2023
We observed a rebound in consumption of antibacterials for systemic use (ATC J01) in the community sector in the European Union/European Economic Area during 2021 and 2022, after an observed decrease between 2019 and 2020. The rates in 2022 returned to pre-COVID-19-pandemic levels and were exceeded in 13 countries. Although these patterns could partly be a result of changes in disease transmission during the study period, it could also reflect a lost opportunity to strengthen and reinforce prudent antibiotic use.
Læs mere
138
Efterårets covid-19-vacciner reducerer risikoen for indlæggelse med 75 procent
Statens Serum Institut, 16.11.2023
Tilføjet 16.11.2023
De variantopdaterede covid-19-vacciner, som er rettet mod nyere varianter af coronavirus, og som er blevet givet siden oktober i år, giver god beskyttelse mod alvorlig sygdom.
Læs mere
139
Saltwater Gargling May Help Avoid COVID Hospitalization
Medscape Infectious Diseases, 14.11.2023
Tilføjet 14.11.2023
Gargling and nasal rinsing were associated with a significant reduction in the hospitalization rate for people with COVID; if confirmed, the finding could be helpful in low-resource settings, says researcher. Medscape Medical News
Læs mere
140
COVID-19 Antivirals Can Trigger Viral Rebound
Medscape Infectious Diseases, 14.11.2023
Tilføjet 14.11.2023
Though antivirals are critical for reducing severe COVID-19 symptoms, researchers suggested that the medication may not always be needed for milder cases. Medscape Medical News
Læs mere
141
Pandemic Tied to a 50% Drop in Memory, Executive Function
Medscape Infectious Diseases, 13.11.2023
Tilføjet 13.11.2023
A 50% decline in working memory and executive function among older adults in the United Kingdom during the first year of the COVID-19 pandemic is linked to an increase in known risk factors for dementia. Medscape Medical News
Læs mere
142
What Happens if You Get Both COVID and Flu (or RSV) at Once?
Medscape Infectious Diseases, 12.11.2023
Tilføjet 12.11.2023
Despite our prevention efforts, some unlucky few may contract not just one of these viruses, but two at once or in close succession during the winter season. WebMD Health News
Læs mere
143
Long COVID and Mental Illness: New Guidance
Medscape Infectious Diseases, 11.11.2023
Tilføjet 11.11.2023
Long COVID can exacerbate existing mental health disorders or cause new-onset psychiatric symptoms, but mental illness does not cause long COVID, experts say. Medscape Medical News
Læs mere
144
Smell and Taste Usually Recover After COVID
Medscape Infectious Diseases, 10.11.2023
Tilføjet 10.11.2023
Three years after infection most people could smell or taste effectively again, a new study found. Medscape Medical News
Læs mere
145
Declines in Influenza Vaccination Coverage Among Health Care Personnel in Acute Care Hospitals During the COVID-19 Pandemic - United States, 2017-2023
Morbidity and Mortality Weekly Report (MMWR), 9.11.2023
Tilføjet 9.11.2023
This report describes declines in influenza vaccination coverage among health care personnel working in hospitals during the COVID-19 pandemic.
Læs mere
146
Influenza and Up-to-Date COVID-19 Vaccination Coverage Among Health Care Personnel - National Healthcare Safety Network, United States, 2022-23 Influenza Season
Morbidity and Mortality Weekly Report (MMWR), 9.11.2023
Tilføjet 9.11.2023
This report describes the percentage of health care personnel working in hospitals and nursing homes who received a flu vaccine and the percentage who received a COVID-19 vaccine.
Læs mere
147
A New Long COVID Explanation: Low Serotonin Levels?
Medscape Infectious Diseases, 6.11.2023
Tilføjet 6.11.2023
Could antidepressants hold the key to treating long COVID? Medscape Medical News
Læs mere
148
Second Infection Hikes Long COVID Risk: Expert Q&A
Medscape Infectious Diseases, 6.11.2023
Tilføjet 6.11.2023
Lead researcher Ziyad Al-Aly, MD, spoke with Medscape about his team’s findings, what we know — and don’t — about long COVID, and what it means for physicians treating patients with the condition. Medscape Medical News
Læs mere